Early Stage Breast Cancer Recurrence Linked to High Leukocyte Ratio
|
By LabMedica International staff writers Posted on 23 Mar 2016 |
|
Image: Blood smear showing a segmented neutrophil and a mature lymphocyte with a single large nucleus (Photo courtesy of the University of Utah Medical School).
A high ratio of two types of immune system cell is linked to an increased risk of disease recurrence after a diagnosis of early stage breast cancer and the findings might guide future treatment and monitoring strategies, if prospective studies confirm the link.
Breast cancer is a commonly diagnosed malignancy and the leading cause of cancer death in women worldwide and despite the widespread adoption of adjuvant treatments having resulted in improved survival, nearly 20% of patients with breast cancer still suffer from recurrence of disease.
Scientists at the Second University of Naples School of Medicine (Caserta, Italy) carried out a retrospective study of A total of 300 female patients with histologically proven early (T1–2, N0–1, non-metastatic) breast cancer treated from July 1999 to June 2015. The following data were collected: age, menopausal status, histological tumor type, tumor size, tumor-node-metastasis stage, and degree of histological differentiation, expression of estrogen and/or progesterone receptor, human epidermal growth factor receptor (HER2) status, Ki67 levels, recurrence rate and distant metastasis–free survival (DMFS) rates.
The ratio of neutrophils to lymphocytes (NLR) ranged from 0.21 to 30.00 (mean 2.67±2.52, median 2.09) in the 300 patients. A significant NLR increase was observed only with T2 stage cancer, and NLR had the ability to distinguish between relapsing and non-relapsing patients. On the basis of their blood counts taken after diagnosis, but before treatment, 134 of the women had a low NLR of 1.97 or lower and 166 had a high NLR above 1.97. After 15 years, cancer had returned in another part of the body in 37 (12%) of the women. Women with a low NLR fared better at each of the subsequent check-ups at 1, 3, 6, 9, 12, and 15 years, with, respectively, 100%, 98.9%, 91.7%, 82.7%, 82.7%, and 82.7% of them free of recurrence. This compares with comparable figures of 99.4%, 94.3%, 84.5%, 69.2%, 66%, and 51.4% at the same time points in those with a high NLR.
The authors concluded that despite looking apparently simple, the relationship between NLR and outcome in patients with cancer is probably a complex and multifactorial process that is still poorly understood. In simple terms, a high NLR may reflect the key role of systemic inflammation in enhancing angiogenesis (formation of new blood vessels), tumor growth, and development of metastasis. The study was published on March 7, 2016, in the journal ESMO Open.
Related Links:
Second University of Naples School of Medicine
Breast cancer is a commonly diagnosed malignancy and the leading cause of cancer death in women worldwide and despite the widespread adoption of adjuvant treatments having resulted in improved survival, nearly 20% of patients with breast cancer still suffer from recurrence of disease.
Scientists at the Second University of Naples School of Medicine (Caserta, Italy) carried out a retrospective study of A total of 300 female patients with histologically proven early (T1–2, N0–1, non-metastatic) breast cancer treated from July 1999 to June 2015. The following data were collected: age, menopausal status, histological tumor type, tumor size, tumor-node-metastasis stage, and degree of histological differentiation, expression of estrogen and/or progesterone receptor, human epidermal growth factor receptor (HER2) status, Ki67 levels, recurrence rate and distant metastasis–free survival (DMFS) rates.
The ratio of neutrophils to lymphocytes (NLR) ranged from 0.21 to 30.00 (mean 2.67±2.52, median 2.09) in the 300 patients. A significant NLR increase was observed only with T2 stage cancer, and NLR had the ability to distinguish between relapsing and non-relapsing patients. On the basis of their blood counts taken after diagnosis, but before treatment, 134 of the women had a low NLR of 1.97 or lower and 166 had a high NLR above 1.97. After 15 years, cancer had returned in another part of the body in 37 (12%) of the women. Women with a low NLR fared better at each of the subsequent check-ups at 1, 3, 6, 9, 12, and 15 years, with, respectively, 100%, 98.9%, 91.7%, 82.7%, 82.7%, and 82.7% of them free of recurrence. This compares with comparable figures of 99.4%, 94.3%, 84.5%, 69.2%, 66%, and 51.4% at the same time points in those with a high NLR.
The authors concluded that despite looking apparently simple, the relationship between NLR and outcome in patients with cancer is probably a complex and multifactorial process that is still poorly understood. In simple terms, a high NLR may reflect the key role of systemic inflammation in enhancing angiogenesis (formation of new blood vessels), tumor growth, and development of metastasis. The study was published on March 7, 2016, in the journal ESMO Open.
Related Links:
Second University of Naples School of Medicine
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Immunofluorescence Analyzer
IFA System
Electrolyte Analyzer
CBS-4000 (CBS-400)
Latest Pathology News
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read more
Molecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read more
Hematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more
